Examining mRNA vaccine effectiveness for immunocompromised adults during omicron BA.4 and BA.5 predominance
Development of vision in early childhood: No screens before age two
26 October 2022How severe is the SARS-CoV-2 omicron BA.2 subvariant compared with earlier variants?
26 October 2022Examining mRNA vaccine effectiveness for immunocompromised adults during omicron BA.4 and BA.5 predominance
A new study from the Centers for Disease Control and Prevention’s VISION Network presents and analyzes some of the first real-world data on mRNA COVID vaccine effectiveness during omicron BA.4 and BA.5 predominance for immunocompromised adults.
